CA2145382A1 - Methodes et compositions pour le traitement anticancereux et pour prevoir la reponse a ce traitement - Google Patents

Methodes et compositions pour le traitement anticancereux et pour prevoir la reponse a ce traitement

Info

Publication number
CA2145382A1
CA2145382A1 CA002145382A CA2145382A CA2145382A1 CA 2145382 A1 CA2145382 A1 CA 2145382A1 CA 002145382 A CA002145382 A CA 002145382A CA 2145382 A CA2145382 A CA 2145382A CA 2145382 A1 CA2145382 A1 CA 2145382A1
Authority
CA
Canada
Prior art keywords
cells
neu
cell
product
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002145382A
Other languages
English (en)
Inventor
Sarah S. Bacus
Yosef Yarden
Michael Sela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Sarah S. Bacus
Yosef Yarden
Michael Sela
Becton, Dickinson And Company
Yeda Research And Development Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL99284A external-priority patent/IL99284A0/xx
Application filed by Sarah S. Bacus, Yosef Yarden, Michael Sela, Becton, Dickinson And Company, Yeda Research And Development Co., Ltd. filed Critical Sarah S. Bacus
Priority claimed from CA002096417A external-priority patent/CA2096417C/fr
Publication of CA2145382A1 publication Critical patent/CA2145382A1/fr
Abandoned legal-status Critical Current

Links

CA002145382A 1991-08-22 1992-08-21 Methodes et compositions pour le traitement anticancereux et pour prevoir la reponse a ce traitement Abandoned CA2145382A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IL99284A IL99284A0 (en) 1991-08-22 1991-08-22 Monoclonal antibodies to a growth factor receptor
IL99284 1991-08-22
US76704291A 1991-09-27 1991-09-27
US76704191A 1991-09-27 1991-09-27
US07/767,042 1991-09-27
US07/767,041 1991-09-27
CA002096417A CA2096417C (fr) 1991-08-22 1992-08-21 Methodes et compositions pour le traitement du cancer et pour predire les reactions a la therapie anticancereuse

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002096417A Division CA2096417C (fr) 1991-08-22 1992-08-21 Methodes et compositions pour le traitement du cancer et pour predire les reactions a la therapie anticancereuse

Publications (1)

Publication Number Publication Date
CA2145382A1 true CA2145382A1 (fr) 1993-03-04

Family

ID=27427038

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002145382A Abandoned CA2145382A1 (fr) 1991-08-22 1992-08-21 Methodes et compositions pour le traitement anticancereux et pour prevoir la reponse a ce traitement

Country Status (1)

Country Link
CA (1) CA2145382A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269776A (zh) * 2019-04-18 2022-04-01 耶达研究及发展有限公司 源自活化car-t细胞的细胞外囊泡

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269776A (zh) * 2019-04-18 2022-04-01 耶达研究及发展有限公司 源自活化car-t细胞的细胞外囊泡

Similar Documents

Publication Publication Date Title
EP0554441B1 (fr) Procedes et compositions de traitements de cancers et de pronostic de reactions auxdits traitements
US5288477A (en) Method for prognosticating response to cancer therapy
Bacus et al. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells
US10365283B2 (en) Activated HER3 as a marker for predicting therapeutic efficacy
AU679247B2 (en) Monoclonal antibodies against the alpha PDGF receptor and uses thereof
Oliva et al. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99m Tc
CN106604933A (zh) 抗pd‑l1抗体及其诊断用途
NO319586B1 (no) Monoklonale antistoffer som gjenkjenner TIE-reseptor og deres anvendelse
JP2007186523A (ja) 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO2006015079A2 (fr) Agents de liaison de la famille erm et leur utilisation dans le diagnostic et le traitement d'etats proliferatifs
Schmitt-Gräff et al. α-smooth muscle actin is expressed in a subset of bone marrow stromal cells in normal and pathological conditions
March et al. Identification and functional characterization of the hepatic stellate cell CD38 cell surface molecule
Neville et al. Monoclonal antibodies and human tumor pathology
Friess et al. A subgroup of patients with chronic pancreatitis overexpress the c-erb B-2 protooncogene
Kamma et al. Characterization of hnRNP A2 and B1 using monoclonal antibodies: intracellular distribution and metabolism through cell cycle
AU2007278792A1 (en) Cancerous disease modifying antibodies
CA2145382A1 (fr) Methodes et compositions pour le traitement anticancereux et pour prevoir la reponse a ce traitement
CA2175247A1 (fr) Ligand pour cd6
KR20090057970A (ko) Ｃｄ63의 세포 표면 발현을 증명하는 세포독성 중재
Kate et al. Immunohistochemical localization of adenosine deaminase complexing protein in intestinal mucosa and in colorectal adenocarcinoma as a marker for tumour cell heterogeneity
US20080267955A1 (en) Frizzled 9 as tumor marker
US20040115741A1 (en) Method of quantifying antigen expression
Millar et al. A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro
IL103250A (en) Methods for pre-determining responses to cancer treatment
CN110386981A (zh) 抗gitr抗体及其用途

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead